


CANM
SCIENTIFIC
CONFERENCE



ACMIN
CONFÉRENCE
SCIENTIFIQUE

OTTAWA
2026



OCT 2 - 4 @ Fairmont Château Laurier

2026 CANM ANNUAL CONFERENCE

OBJECTIVES OF THE CONFERENCE:

1. Maintain competence on a wide variety of up-to-date topics in Nuclear Medicine
2. Discuss hot new topics
3. Establish a network of Nuclear Medicine specialists
4. Promote Nuclear Medicine as a specialty

Please note that 25% of allowed time to each speaker will be reserved for questions from participants.

OBJECTIFS GÉNÉRAUX DE LA CONFÉRENCE :

1. Maintenir la compétence sur une grande variété de sujets d'actualité en médecine nucléaire
2. Discuter de nouveaux sujets d'actualité
3. Établir un réseau de spécialistes en médecine nucléaire
4. Promouvoir la médecine nucléaire en tant que spécialité

Veillez noter que 25 % du temps alloué à chaque orateur sera réservé aux questions des participants.

2026 CANM ANNUAL CONFERENCE

FRIDAY, October 2nd, 2026

0800 - 1830	REGISTRATION	French Corridor
0830 - 1330	PATIENT EDUCATION & ADVOCACY DAY <i>by invitation only</i>	MacDonald Room
1200 - 1830	EXHIBITS SET-UP	French Corridor / Laurier Room
1200 - 1830	POSTERS / DISPLAY SET-UP	Ballroom
1315 - 1700	CANM Board meeting (<i>board members only</i>)	Diefenbunker: Canada's Cold War Museum
	Chair: François Lamoureux	
1700 - 1830	NATIONAL CAREER DAY	MacDonald Room (Hybrid)
	Host: Debra Dawson	
1830 - 2000	OPENING CEREMONY COCKTAIL	French Corridor / Laurier Room

2026 CANM ANNUAL CONFERENCE

FRIDAY, October 2nd, 2026

0830 - 1330 **PATIENT EDUCATION & ADVOCACY DAY** **MacDonald Room**
by invitation only

A national, patient-focused conversation about nuclear medicine, molecular imaging, radioligand therapy and equitable access to care across Canada.

0830 - 0850 **Registration, Refreshments & Patient-Organization Showcase**
 Welcome coffee, registration and an opportunity to visit participating patient organizations.

0850 - 0900 **Welcome & Opening Remarks**
 Setting the stage for a patient-centred morning of education, dialogue and advocacy.

UNDERSTANDING NUCLEAR MEDICINE | Education

0900 - 0920 **From Isotope Production to Patient Care** Holly Bilton (CPDC)
 How medical isotopes and radiopharmaceuticals are produced, prepared and delivered for patient use.

0920 - 0945 **Inside a Nuclear Medicine Department** Mary Dalipaj
 The equipment and people behind patient care: nuclear medicine physicians, technologists and radiopharmaceutical scientists. Jaden Bardens, MRT(N), HBSc

0945 - 1005 **Molecular Imaging: Seeing Disease Differently** Dr. Debra Dawson
 Key indications in molecular imaging and its benefits in oncology— from earlier detection to more personalized care. Dr. James Curtis

1005 - 1030 **See It, Measure It, Treat It: Introduction to RLT** Dr. Stella Koumna
 How molecular imaging and radioligand therapy connect diagnosis, treatment selection and targeted therapy. Dr. Freimut Juengling

THE PATIENT PERSPECTIVE | Lived Experience

1030 - 1055 **A Patient's Journey Through Nuclear Medicine – Jean Krashevski** Jean Krashevski
 A lived experience with cancer, molecular imaging, treatment decisions and radioligand therapy.

1055 - 1115 **REFRESHMENT BREAK & NETWORKING**
 Patient-organization showcase continues

2026 CANM ANNUAL CONFERENCE

FRIDAY, October 2nd, 2026

GLOBAL PERSPECTIVE

1115 - 1135 **Strengthening Medical Imaging Worldwide: The WHO - WHA78.13 Resolution**
Prof. John Prior, MD, PhD, FEBNM, FSNMMI
Treasurer, World Federation of Nuclear Medicine & Biology (WFNMB)

NATIONAL ACCESS DIALOGUE | Advocacy panel

1135 - 1240 **The Future of Nuclear Medicine: National Access Panel**
A national discussion with patients, clinicians, advocacy organizations and government on current challenges, future opportunities and equitable access across Canada.

Moderator: Kurtis Billard - Nuclear Medicine & PET/CT Technologist

Panelists:

- Al Carl - Patient Representative
- Dr. Freimut Juengling - CANM
- Dr. Stella Koumna - CANM
- Stephen Piazza - Canadian Cancer Society
- Jaden Bardens - Nuclear Medicine & PET/CT Technologist
- Jacqueline Metzler - Siemens Healthineers

1240 - 1255 **Audience Questions & Key Takeaways**
Questions and perspectives from patients, advocacy organizations and participants.

1255 - 1305 **Closing Remarks**
Reflections and next steps

1305 - 1330 **Networking Lunch & Patient-Organization Showcase**
Continue the conversation with patients, clinicians, advocates, government and partners.

1700 - 1830 **NATIONAL CAREER DAY** MacDonald Room (Hybrid)

Host: Debra Dawson

1830 - 2000 **OPENING CEREMONY COCKTAIL** French Corridor / Laurier Room

END OF DAY – FIN DE LA JOURNÉE

2026 CANM ANNUAL CONFERENCE

SATURDAY, October 3rd, 2026

0700 - 1700	REGISTRATION-INSCRIPTION	French Corridor
0800 - 1700	EXHIBITS CONTINUE	French Corridor / Laurier Room
0800 - 1700	POSTERS ON DISPLAY	Ballroom
0840 - 0845	OPENING CEREMONY	Ballroom
0845 - 1000	SESSION #1-A, Section III <i>Case based review: PSMA Imaging and Radioligand Therapy Assessment in Prostate Cancer</i> Chair: Andrew Ross Objectives: 1. Review the role and limitations of PSMA imaging in prostate cancer 2. Clinical and imaging assessment of eligibility for Lu-177 PSMA therapies 3. Evaluation of treatment response and progression using PSMA imaging 4. Focus on PCWG4 and RECIP 1.0 frameworks 5. Translation of imaging findings into management decisions	Dr. James Curtis Ballroom
1000 - 1030	REFRESHMENT BREAK	French Corridor / Laurier Room
1030 - 1215	SESSION #2 – METER COURSE Chair: Brandon Hardy & Carl Jarvis Co-Chair: Peter George Maliha Objectives: 1. Describe the roles and responsibilities of the Radiation Safety Officer and emergency physician when responding to a radiological incident. 2. Apply a structured approach to the initial assessment, decontamination, and clinical management of patients involved in a radiation emergency. 3. Identify appropriate radiation-protection measures for patients, personnel, and the public. 4. Integrate clinical and radiation-safety perspectives into coordinated emergency-response planning.	Ballroom
1030 - 1100	Radiation-Safety Response: initial notification, contamination control, decontamination, staff protection and the RSO's responsibilities	Brandon Hardy
1100 - 1140	Emergency-Medicine Response: triage, clinical stabilization, assessment, treatment priorities and coordination with the RSO	Carl Jarvis
1140 - 1205	Joint case walkthrough with audience polling at key decision points	Brandon Hardy, Carl Jarvis, Peter George Maliha
1205 - 1215	Q&A	
1215 - 1315	LUNCHEON	French Corridor / Laurier Room
1300 - 1315	NCNMC presentation by Mina Bechai	Ballroom

2026 CANM ANNUAL CONFERENCE

SATURDAY, October 3rd, 2026

1315 - 1515 **SESSION #3 – ALPHA THERAPIES** **Ballroom**

Chair: Peter George Maliha

Objectives:

1. *Evaluate the current clinical and research status of 225Ac-labeled agents*
2. *Describe the clinical outcomes, therapeutic efficacy, and toxicity profiles of 225Ac-PSMA-Trillium in the treatment of advanced prostate cancer*
3. *Integrate the perspectives of both Oncology and Nuclear Medicine to formulate a collaborative clinical management plan regarding 225Ac-labeled PSMA therapy agents*

1315 - 1345	Alpha-Emitting Radiopharmaceutical Therapies: Current evidence and future directions	Farzad Abbaspour
-------------	--	------------------

1345 - 1415	Actinium-225-PSMA-trillium – Med Onc perspective	Zineb Hamilou
-------------	--	---------------

1415 - 1445	Actinium-225-PSMA-trillium – Nuc Med perspective	Daniel Juneau
-------------	--	---------------

1445 - 1515	Q&A	
-------------	----------------	--

1515 - 1530 **REFRESHMENT BREAK** **French Corridor/ Laurier Room**

1530 - 1545 **OSNM Presentation by Neena Kanwar** **Ballroom**

1545 - 1700 **AFTERNOON TEA SYMPOSIUM**
Best Practice Report Consensus Meeting **Ballroom**

Chair: Patrick Veit-Haibach

Presenters:

- Scott Morgan (Rad Onc)
- Frederic Pouliot (Urology)
- Michael Ong (Med Onc)

Objectives:

1. *Summarize the principal recommendations of the multidisciplinary expert report concerning PSMA PET staging, lutetium radioligand therapy, and nuclear medicine strategies in prostate cancer.*
2. *Apply consensus-based criteria for patient selection, multidisciplinary approval, assessment, treatment monitoring, and post-infusion care for lutetium therapy.*
3. *Compare the perspectives and responsibilities of urology, medical oncology, radiation oncology, and nuclear medicine when implementing PSMA-based diagnostic and theranostic pathways.*
4. *Discuss areas of ongoing clinical uncertainty and identify practical strategies for incorporating the recommendations into Canadian practice.*

2026 CANM ANNUAL CONFERENCE

SATURDAY, October 3rd, 2026

1700 - 1800

**ABSTRACTS AND POSTER PRESENTATIONS
& ERIC LEPP COMPETITION WINNER PRESENTATION**

Ballroom

Scientific Committee Chair: Andrew Ross

1700 - 1710

Best General Abstract

Ghazal Norouzi

A Comparative Analysis of Human and Artificial Intelligence
Performance in Detecting Synthetic Lesions in Positron Emission
Tomography Imaging

1710 - 1722

PET Perfusion Imaging in Hypertrophic Cardiomyopathy

Amir Aker

1722 - 1734

FDG PET-Derived Brain Age Gap Identifies a Trajectory-Sensitive
Metabolic Ageing Phenotype in Mild Cognitive Impairment

Jarrad Perron

1734 - 1746

Eric Lepp Award recipient

Hassan Bachir
Melhem

Resolution of Microvascular Ischemia Following Alcohol Septal
Ablation in Hypertrophic Cardiomyopathy: Evidence from
Rubidium-82 PET

1746 - 1800

Q&A

1830 - 1930

*NETWORKING COCKTAIL
+ ABSTRACTS AND POSTER PRESENTATIONS*

French Corridor / Laurier Room

1930 - 2230

GALA – CANM/ACMN

Canadian Room

END OF DAY – FIN DE LA JOURNÉE

SUNDAY, October 4th, 2026

0900 - 1200

REGISTRATION-INSCRIPTION

French Corridor

0900 - 1300

EXHIBITS CONTINUE

French Corridor / Laurier Room

0900 - 1730

POSTERS ON DISPLAY

Ballroom

2026 CANM ANNUAL CONFERENCE

SUNDAY, October 4th, 2026

0900 - 1000

SUNRISE LEARNING – BREAKFAST

Ballroom

Chair: Jonathan Boekhoud

Neuroimaging in Alzheimer's Disease: From Molecular Biomarkers to Clinical Management Objectives:

1. Describe the biological targets and imaging principles underlying tau and neuroinflammation PET in Alzheimer's disease.
2. Compare established and emerging imaging and fluid biomarkers used in the assessment of Alzheimer's disease, including their respective clinical and research applications.
3. Identify when PET imaging may be appropriate in the diagnostic evaluation of patients with cognitive impairment and explain how the results can influence clinical management.
4. Discuss how emerging biomarkers, molecular imaging approaches, and disease-modifying therapies may affect future diagnostic and treatment pathways in Alzheimer's disease.

0900 - 0915	Mapping the Dual Pathology: Tau and Neuroinflammation PET Imaging in Alzheimer's Disease	Karine Provost
-------------	--	----------------

0915 - 0930	Biomarkers in AD: Clinical and Research Perspectives.	Paolo Vitali
-------------	---	--------------

0930 - 0945	Impact of PET scans on clinical management of AD - an evolving landscape	Chenjie Xia
-------------	--	-------------

0945 - 1000	Q&A	
-------------	-----	--

1000 - 1200

SESSION #4-B – SECTION III

Ballroom

Chair: Frédéric Arsenault

Objectives:

1. Identify and characterize relevant scintigraphic and radiologic abnormalities in challenging SPECT/CT and non-oncological PET cases.
2. Integrate imaging findings with the clinical information provided to establish the most appropriate diagnosis and recommend further management when indicated.
3. Apply current practice guidelines and recognized interpretation criteria to both common and less frequently encountered cases.
4. Recognize important interpretive pitfalls and incidental findings, assess their clinical significance, and recommend appropriate additional investigations when necessary.

1000 - 1100	Interactive SPECT/CT Case Review: Interpretation, Pitfalls and Clinical Management	Khun Visith Keu
-------------	--	-----------------

1100 - 1200	Interactive Non-Oncological PET Case Review: Guidelines, Pitfalls and Clinical Applications	Sylvain Prévost
-------------	---	-----------------

2026 CANM ANNUAL CONFERENCE

SUNDAY, October 4th, 2026

1200 - 1300	LUNCHEON	French Corridor / Laurier Room
1235 - 1300	CMIE Luncheon Symposium - <i>The Past, Present, and Future of Canada's Medical Isotope Ecosystem</i> <i>Presenter:</i> Holly Bilton PhD — Chair, Canadian Medical Isotope Ecosystem (CMIE); Associate Director, Business Development, CPDC Objectives: 1. Review key milestones in Canada's medical isotope and radiopharmaceutical ecosystem. 2. Examine barriers to innovation, clinical translation, manufacturing, workforce development and patient access. 3. Explore collaboration opportunities to strengthen Canada's radiopharmaceutical sector.	Ballroom
1330 - 1500	INDUSTRY FORUM <i>for sponsors by invitation only</i>	MacDonald Room
1300 - 1545	SESSION #5 – CARDIAC <i>Chair:</i> Terry Ruddy Objectives: 1. Review the role of advanced cardiac molecular imaging techniques in the diagnosis and management of cardiovascular disease. 2. Apply quantitative PET and SPECT myocardial blood flow measurements to improve clinical decision-making in patients with suspected or known coronary artery disease. 3. Recognize common pitfalls and interpretive challenges in PET imaging for cardiac sarcoidosis and infective endocarditis. 4. Evaluate the clinical applications of quantitative imaging in cardiac amyloidosis and myocardial perfusion imaging. 5. Integrate evidence-based interpretation of interactive cardiac imaging cases into routine nuclear cardiology practice.	Ballroom
1300 - 1330	Cardiac Amyloidosis and Advanced Imaging Quantification	Gary Small
1330 - 1400	Challenges And Pitfalls in PET Reporting of Cardiac Sarcoidosis and Endocarditis	Kevin Boczar
1400 - 1430	Quantification of Myocardial Blood Flow with SPECT Imaging	Glenn Wells
1430 - 1500	PET Quantification of Myocardial Blood Flow: Clinical Applications and Interpretation	Rob deKemp
1500 - 1530	Interactive Teaching Cases in Myocardial Perfusion Imaging	Benjamin Chow
1530 - 1545	Q&A	
1545 - 1615	REFRESHMENT BREAK	French Corridor / Laurier Room

2026 CANM ANNUAL CONFERENCE

SUNDAY, October 4th, 2026

1615 - 1830

SESSION #6 – IN THE PIPELINE

Ballroom

Chairs: François Lamoureux & Jonathan Boekhoud

Objectives:

1. *Review emerging PET radiotracers and radiopharmaceuticals that are expected to influence future nuclear medicine practice.*
2. *Discuss the clinical applications and evolving evidence supporting novel tracers in neuro-oncology, renal oncology, and FAPI imaging.*
3. *Evaluate how these emerging imaging agents may improve patient selection, diagnosis, and treatment planning.*
4. *Recognize the potential impact of ongoing clinical trials and new technologies on the future of precision medicine and theranostics.*

1615 - 1645	Neuro-oncology (18F-FET, theranostics, IPAX BrIGHT trial)	Nabil Elshafeey
1645 - 1715	Renal oncology (ZIRCON / girentuximab and newer RCC data)	Aimal Ahmed
1715 - 1745	FAPI – Fibroblast activation protein inhibitor	Étienne Rousseau
1745 - 1815	Matched Radionuclides for Imaging and Therapy	Suzy Lapi
1815 - 1830	Q&A	

CLOSURE – FERMETURE

2026 CANM ANNUAL CONFERENCE

SCIENTIFIC COMMITTEE – OTTAWA 2026

Andrew Ross
Cheryl Jefford
Olfat Kamel Hasan
Salem Yuoness
Peter George Maliha

Debra Dawson
Lionel Zuckier
Eugene Leung
Christiane Wiefels

This activity has been made possible thanks to the educational support of the following sponsors:

La tenue de cette activité a été rendue possible grâce à une subvention à visée éducative de:

Novartis
CPDC / CMIE
Cyclomedica
Siemens Healthineers
Hermes Medical Solutions
GE Healthcare
MIM Software, a GE Healthcare Company

Isologic
Initio Medical
Bayer
Telix
Curium
Mirion Technologies
Jubilant Radiopharma / Eckert & Ziegler

A special thanks to the following exhibitors:

Nous tenons à remercier les exposants suivants :

WELL Health
Spectrum Dynamics Medical
VigTech Imaging Solutions
Lemer Pax
SHINE Technologies

Eckert & Ziegler
Medron Medical Systems Inc.
Best Theratronics Ltd.
Insight Medical
Convergent Imaging

BC Cancer / Provincial Health Services
The Ottawa Hospital
Ontario Society of Nuclear Medicine
Newfoundland & Labrador Health Services

For more information, please visit our website at:

Pour plus d'information, visitez notre site web :

www.canm-acmn.ca